{
    "nctId": "NCT05212454",
    "briefTitle": "Efficacy of Supplement Adjuvant Capecitabine in HR+/HER2- Breast Cancer Patients With High Risks",
    "officialTitle": "Efficacy and Safety of Supplement Adjuvant Capecitabine in Postoperative Hormone Receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative High-risk Breast Cancer Patients: a Multicenter, Single-arm Clinical Trial",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer, Chemotherapy Effect",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 400,
    "primaryOutcomeMeasure": "disease free survival",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Female, age 18-70 years.\n* Completed radical breast cancer surgery with confirmed pathology suggested primary invasive breast adenocarcinoma, ER and/or PR positive (defined as positive cells \\>1%) and HER2 negative (defined as HER2 immunohistochemistry 2+ or less and FISH negative).\n* Definition of high-risk factors: 4 or more positive axillary lymph nodes; 1-3 positive axillary lymph nodes with primary tumor \u2265 5 cm or histologic grade 3 or ki67 \u2265 20%; or residual lesions despite neoadjuvant chemotherapy.\n* No prior treatment for present breast cancer onset.\n* ECOG physical status score 0 to 1\n* Hematological examination before treatment should meet: white blood cell count (WBC) \u2265 4.0\u00d710\\^9/L, neutrophil count (ANC) \u2265 1.5\u00d710\\^9/L, platelet count (PLT) \u2265 100\u00d710\\^9/L; hemoglobin (Hb) \u2265 90g/L; AST (sGOT), ALT (sGPT) \u2264 1.5 times the normal value upper limit, creatinine \u2264 1.5 times the upper limit of normal value, total bilirubin \u2264 1.5 times the upper limit of normal value.\n* No serious impairment of heart, liver, kidney and other important organ functions.\n\nExclusion Criteria:\n\n* Unwilling or unable to use an acceptable method of contraception for up to and including 8 weeks after the final dose of the test drug.\n* Women during pregnancy and breastfeeding after pregnancy.\n* Women with proven distant metastases of breast cancer.\n* Patients with proven sensory or motor nerve disease.\n* Definite cardiovascular disease, severe co-morbidity or active infection, including known HIV infection.\n* Patients who need long-term anticoagulant drugs for cardiovascular or thrombotic diseases.\n* History of other tumors.\n* Allergic to the study drug or its excipients, etc.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}